Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Figures & data

Table 1 Characteristics of the Study Population

Number of Patients	42
Sex:
Male	57.1% (n=24)
Female	42.9% (n=18)
Mean Age (years)	49.5±9.2
Mean duration of Psoriasis (years)	14.4±8.6
Psoriatic arthritis	21.4% (n=9)
Mean duration (years)	3.9±4.2
Comorbidities:
Hypertension	45.2% (n=19)
Dyslipidaemia	28.6% (n=12)
Diabetes	16.6% (n=7)
Cardiopathy	14.2% (n=6)
Depression	11.9% (n=5)
Thyroiditis	9.5% (n=4)
Glaucoma	4.7% (n=2)
BPH	4.7% (n=2)
Previous conventional systemic treatments:
Methotrexate	64.3% (n=27)
Cyclosporine	40.5% (n=17)
Acitretin	42.3% (n=15)
Nb-UVB Phototherapy	16.6% (n=7)
Bio-naïve patients	45.2% (n=19)
Previous biologic treatments
Anti- TNF
Adalimumab	30.9% (n=13)
Etanercept	7.1% (n=3)
Infliximab	2.4% (n=1)
Certolizumab	4.7% (n=2)
Golimumab	7.1% (n=3)
Anti- IL-12/23
Ustekinumab	11.9% (n=5)
Anti-IL-17
Ixekizumab	9.5% (n=4)
Secukinumab	7.1% (n=3)
Brodalumab	4.7% (n=2)
Anti-IL-23
Guselkumab	4.7% (n=2)
Risankizumab	2.4% (n=1)

Abbreviations: BPH, Benign prostatic hyperplasia; Nb-UVB, Narrow band UVB; IL, interleukin; TNF, Tumor necrosis factor.

Table 2 Clinical Outcomes During Tildrakizumab Treatment

	Baseline	Week 16	Week 28	Week 52
Mean PASI	13.5 ± 5.9	5.4 ± 4.2	2.8 ± 3.8	2.9 ± 4.2
Mean BSA	19.6 ± 14.8	10.4 ± 6.3	4.7 ± 4.9	4.9 ± 4.2
DLQI	18.4 ± 8.5	8.2 ± 4.2	5.4 ± 3.6	5.8 ± 4.2
PASI90	N/A	52.4% (n = 23)	76.1% (n = 32)	73.8% (n = 31)
PASI100	N/A	33.3% (n = 14)	61.9% (n = 26)	59.5% (n = 25)
Discontinuation rate	N/A	4.7% (n = 2)	7.1% (n = 3)	11.9% (n = 5)
Total number of patients	42	40	39	37

Abbreviations: BSA, Body Surface Area; PASI, Psoriasis Area Severity Index.

Figure 1 Rates of PASI90 and PASI100 responses achieved during tildrakizumab treatment.

Table 3 Reported Adverse Events During Tildrakizumab Treatment Up to 52 Weeks Follow-Up

Adverse Events
Pharyngitis	11.9% (n=5)
Flu-like illness	9.5% (n = 4)
Headache	7.1% (n = 3)
Diarrhoea	2.4% (n=1)
Injection site reaction (pain)	7.1% (n = 3)